Dasatinib API

Name	Dasatinib
Chinese name	达沙替尼
Cas Number	863127-77-9
Source	India
Qualifications	USDMF/-/-/-/-

Dasatinib is an oral tyrosine kinase inhibitor developed by Bristol-Myers Squibb. The drug passed the priority approval of the US FDA on June 28, 2006. It is used for failure or intolerance to previous treatments. Adult patients with chronic myeloid leukemia (CML) in all disease stages, and also used to treat Philadelphia chromosome-positive adult patients with acute lymphoblastic leukemia (ph+ALL) who are resistant or intolerant to other therapies. Dasatinib has an inhibitory effect on a variety of mutants of Bcr-Ab1 kinase, and its inhibitory strength is greatly improved compared with imatinib. In the in vitro test, its kinase inhibitory ability is 325 times that of imatinib, and it is not found Resistance. Currently the drug has been approved in most countries around the world. The curative effect is longer and the safety is higher. However, in addition to leukemia, Dasatinib also has great potential to treat other tumors. A number of clinical trials are currently underway to test the therapeutic effects of dasatinib on melanoma, prostate cancer, pancreatic cancer, endometrial cancer, gastrointestinal stromal cancer, and ovarian cancer. The total global sales of dasatinib in 2018 was 14.5 billion yuan.

Hot Tags: dasatinib api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Deoxycholic Acid API, Temozolomide API, Brinzolamide API, Vardenafil API, Lurasidone Hydrochloride API, Active Pharmaceutical Ingredient

• Previous: Carbidopa API
• Next: Epinephrine Tartrate API